Ingredient or product comparison
GHK-Cu 30s Age Protocol: Subcutaneous vs Topical Comparison
Subcutaneous injection 0.5–1.0mg per session, 2–3× weekly ~85–95% (direct dermal deposition) Generalized collagen maintenance, systemic signaling support Low. Plasma clearance within 90 minutes Best choice for 30s users prioritizing prevention over spot correc
This source-based comparison does not add ratings or recommend a winner.
- Subcutaneous injection
- 0.5–1.0mg per session, 2–3× weekly
- ~85–95% (direct dermal deposition)
- Generalized collagen maintenance, systemic signaling support
- Low. Plasma clearance within 90 minutes
- Best choice for 30s users prioritizing prevention over spot correction; bypasses epidermal barrier that's still structurally intact at this age
- Topical (liposomal)
- 2–3mg per application, daily
- ~8–12% (epidermal penetration)
- Targeted early photoaging (periorbital, forehead), localized fine lines
- Moderate. Prolonged epidermal contact can accumulate copper in stratum corneum
- Effective for spot treatment; less reliable for systemic collagen signaling due to penetration limits in thicker 30s skin
- Topical (DMSO-based)
- 2–3mg per application, 3–4× weekly
- ~15–20% (enhanced penetration)
- High-movement zones (crow's feet, nasolabial folds) where epidermal barrier is thinner
- Moderate to high. DMSO increases systemic absorption
- Use sparingly; penetration enhancement raises copper exposure risk without proportional collagen benefit in this age group
- The comparison underscores a key point: in your 30s, your skin's barrier function is still robust. Topical delivery works better once that barrier has degraded. Which typically happens after 45. Until then, subcutaneous administration is the more efficient route for systemic collagen signaling.